These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15293982)

  • 21. Imidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes.
    Chen P; Caldwell CG; Mathvink RJ; Leiting B; Marsilio F; Patel RA; Wu JK; He H; Lyons KA; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5853-7. PubMed ID: 17869513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective.
    Deacon CF; Holst JJ
    Biochem Biophys Res Commun; 2002 May; 294(1):1-4. PubMed ID: 12054731
    [No Abstract]   [Full Text] [Related]  

  • 23. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus.
    McIntosh CH; Demuth HU; Kim SJ; Pospisilik JA; Pederson RA
    Int J Biochem Cell Biol; 2006; 38(5-6):860-72. PubMed ID: 16442340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors.
    Fukushima H; Hiratate A; Takahashi M; Mikami A; Saito-Hori M; Munetomo E; Kitano K; Chonan S; Saito H; Suzuki A; Takaoka Y; Yamamoto K
    Bioorg Med Chem; 2008 Apr; 16(7):4093-106. PubMed ID: 18243000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.
    Ahrén B
    Diabetes Care; 2007 Jun; 30(6):1344-50. PubMed ID: 17337494
    [No Abstract]   [Full Text] [Related]  

  • 26. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.
    Kirby M; Yu DM; O'Connor S; Gorrell MD
    Clin Sci (Lond); 2009 Sep; 118(1):31-41. PubMed ID: 19780719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substituted pyrrolidine-2,4-dicarboxylic acid amides as potent dipeptidyl peptidase IV inhibitors.
    Tsai TY; Coumar MS; Hsu T; Hsieh HP; Chien CH; Chen CT; Chang CN; Lo YK; Wu SH; Huang CY; Huang YW; Wang MH; Wu HY; Lee HJ; Chen X; Chao YS; Jiaang WT
    Bioorg Med Chem Lett; 2006 Jun; 16(12):3268-72. PubMed ID: 16581245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin.
    Taldone T; Zito SW; Talele TT
    Bioorg Med Chem Lett; 2008 Jan; 18(2):479-84. PubMed ID: 18068977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substituted piperazines as novel dipeptidyl peptidase IV inhibitors.
    Brockunier LL; He J; Colwell LF; Habulihaz B; He H; Leiting B; Lyons KA; Marsilio F; Patel RA; Teffera Y; Wu JK; Thornberry NA; Weber AE; Parmee ER
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4763-6. PubMed ID: 15324904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Kim D; Wang L; Beconi M; Eiermann GJ; Fisher MH; He H; Hickey GJ; Kowalchick JE; Leiting B; Lyons K; Marsilio F; McCann ME; Patel RA; Petrov A; Scapin G; Patel SB; Roy RS; Wu JK; Wyvratt MJ; Zhang BB; Zhu L; Thornberry NA; Weber AE
    J Med Chem; 2005 Jan; 48(1):141-51. PubMed ID: 15634008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of potent and selective beta-homophenylalanine based dipeptidyl peptidase IV inhibitors.
    Xu J; Ok HO; Gonzalez EJ; Colwell LF; Habulihaz B; He H; Leiting B; Lyons KA; Marsilio F; Patel RA; Wu JK; Thornberry NA; Weber AE; Parmee ER
    Bioorg Med Chem Lett; 2004 Sep; 14(18):4759-62. PubMed ID: 15324903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Pei Z; Li X; von Geldern TW; Madar DJ; Longenecker K; Yong H; Lubben TH; Stewart KD; Zinker BA; Backes BJ; Judd AS; Mulhern M; Ballaron SJ; Stashko MA; Mika AK; Beno DW; Reinhart GA; Fryer RM; Preusser LC; Kempf-Grote AJ; Sham HL; Trevillyan JM
    J Med Chem; 2006 Nov; 49(22):6439-42. PubMed ID: 17064063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.
    Brigance RP; Meng W; Fura A; Harrity T; Wang A; Zahler R; Kirby MS; Hamann LG
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4395-8. PubMed ID: 20598534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DPP-4 inhibitors. A new class of drugs for type 2 diabetes.
    Marino MT
    Diabetes Self Manag; 2008; 25(4):60, 62-4. PubMed ID: 18717028
    [No Abstract]   [Full Text] [Related]  

  • 35. Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors.
    Qiao L; Baumann CA; Crysler CS; Ninan NS; Abad MC; Spurlino JC; Desjarlais RL; Kervinen J; Neeper MP; Bayoumy SS; Williams R; Deckman IC; Dasgupta M; Reed RL; Huebert ND; Tomczuk BE; Moriarty KJ
    Bioorg Med Chem Lett; 2006 Jan; 16(1):123-8. PubMed ID: 16236500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and biological evaluation of triazolopiperazine-based beta-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors.
    Kowalchick JE; Leiting B; Pryor KD; Marsilio F; Wu JK; He H; Lyons KA; Eiermann GJ; Petrov A; Scapin G; Patel RA; Thornberry NA; Weber AE; Kim D
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5934-9. PubMed ID: 17827003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
    Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity.
    Reinhold D; Kähne T; Steinbrecher A; Wrenger S; Neubert K; Ansorge S; Brocke S
    Biol Chem; 2002; 383(7-8):1133-8. PubMed ID: 12437097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of potent, selective, and orally bioavailable pyridone-based dipeptidyl peptidase-4 inhibitors.
    Xu J; Wei L; Mathvink R; Edmondson SD; Mastracchio A; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Petrov A; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2006 Mar; 16(5):1346-9. PubMed ID: 16332437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. From lead to preclinical candidate: optimization of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV.
    Nordhoff S; López-Canet M; Hoffmann-Enger B; Bulat S; Cerezo-Gálvez S; Hill O; Rosenbaum C; Rummey C; Thiemann M; Matassa VG; Edwards PJ; Feurer A
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4818-23. PubMed ID: 19576767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.